My Portfolio
+
LINK YOUR PORTFOLIO

Allogene Therapeutics Inc ALLO:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 3:15 PM EDT
2.00quote price arrow down-0.05 (-2.68%)
Volume
7,202,126
52 week range
0.98 - 4.46
Loading...
  • Open2.07
  • Day High2.07
  • Day Low1.96
  • Prev Close2.05
  • 52 Week High4.46
  • 52 Week High Date04/13/26
  • 52 Week Low0.98
  • 52 Week Low Date08/07/25

Latest On Allogene Therapeutics Inc

Key Stats

  • Market Cap688.583M
  • Shares Out345.15M
  • 10 Day Average Volume6.90M
  • Dividend-
  • Dividend Yield-
  • Beta0.46

Latest On Allogene Therapeutics Inc

KEY STATS

  • Open2.07
  • Day High2.07
  • Day Low1.96
  • Prev Close2.05
  • 52 Week High4.46
  • 52 Week High Date04/13/26
  • 52 Week Low0.98
  • 52 Week Low Date08/07/25
  • Market Cap688.583M
  • Shares Out345.15M
  • 10 Day Average Volume6.90M
  • Dividend-
  • Dividend Yield-
  • Beta0.46

RATIOS/PROFITABILITY

  • EPS (TTM)-0.77
  • P/E (TTM)-2.60
  • Fwd P/E (NTM)-2.73
  • EBITDA (TTM)-175.705M
  • ROE (TTM)-52.32%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-1,170,864.00%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date08/11/2026(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Profile

MORE
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on three core programs: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID), and Renal Cell Carcinoma (RCC). It is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein...
Arie Belldegrun M.D.
Executive Chairman of the Board
Zachary Roberts M.D., Ph.D.
President, Chief Executive Officer, Interim Chief Medical Officer, Director
Geoffrey Parker
Chief Financial Officer, Executive Vice President
Address
210 East Grand Avenue
South San Francisco, CA
94080
United States